Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.


In July 2020 they have partnered with Leiden University Medical Center (LUMC) to initiate clinical trials for microdosing MDMA/psilocybin formulations. They are also planning to study the use of psilocybin (-assisted therapy) for PTSD in veterans. On which they have also filed a patent (October 2020).

“Leveraging partnerships with scientific, medical, military, and clinical organizations, Mydecine is at the forefront of psychedelic medicine.”

You can find their investor presentation here.

Key Staff

  • Joshua Bartch – Director, CEO, Co-Founder
  • Damon Michaels – Director, COO, Co-Founder
  • Rob Roscow – CSO, Co-Founder
  • Jim Gunning – CMO
  • Michael Connolly – CCO
  • Robin Carhart-Harris – Scientific Advisor
  • David Erritzoe – Scientific Advisor


Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account